Satyanarayana Chava, Founder and CEO of Laurus Labs, said the company has requested Gilead to grant it licence for Remdesivir.
The USFDA earlier gave emergency use authorisation (EUA) to Gilead’s Remdesivir for treatment of hospitalised patients with severe COVID-19 conditions.
"We have requested them to grant license and it is up to Gilead to grant," said Chava.
Chava expects the growth trajectory to continue in the coming quarters.
“In the last few quarters, we were able to increase our gross margins and EBITDA margins, and we expect that growth trajectory will continue in the coming quarters as well,” he said.